查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1725148

2032 年尿激酶市場預測：按類型、來源、給藥途徑、應用、最終用戶和地區進行的全球分析

Urokinase Market Forecasts to 2032 - Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球尿激酶市場預計在 2025 年達到 20.8 億美元，到 2032 年將達到 35 億美元，預測期內的複合年成長率為 7.7%。

尿激酶是一種血栓溶解酶，醫學上用於溶解體內的血栓。它是絲胺酸蛋白酶，最初來自人類尿液，但現在通常使用重組 DNA 技術生產。尿激酶將胞漿素原原轉化為胞漿素，並作為分解纖維蛋白（血塊的主要蛋白質組成）的酶。主要用於治療肺動脈栓塞、深層靜脈栓塞症、導管阻塞等。尿激酶作為纖溶酶原活化劑，在恢復阻塞血管的血流中起著重要作用，使其成為急診和介入醫學的重要治療選擇。

根據英國心臟基金會 2024 年的一篇報導，英國有 760 萬人患有心臟和循環系統疾病。

血栓性疾病盛行率不斷上升

由於對血栓溶解療法的需求增加，血栓疾病的盛行率不斷上升，推動了尿激酶市場的發展。尿激酶用於分解血栓，在治療肺動脈栓塞、深層靜脈栓塞症和急性心肌梗塞中發揮重要作用。隨著這些疾病在全球範圍內的盛行率上升，特別是在老年人口中，對​​有效的溶栓療法的需求也日益增加。這一趨勢有利於尿激酶市場並刺激其生產和應用的進一步發展。

醫療費用高昂

高昂的治療費用嚴重阻礙了尿激酶市場的成長，因為它限制了患者和醫療保健提供者獲得治療的機會，尤其是在中低收入地區。如此高的治療費用限制了尿激酶治療方法的廣泛使用，並導致對更便宜的替代療法的需求。此外，高成本對醫療預算造成壓力，阻礙了保險覆蓋，並限制了廣泛的臨床使用，最終減緩了市場擴張並抑制了溶栓療法的創新。

藥物傳輸技術進步

藥物輸送系統的技術進步對尿激酶市場產生了重大影響，提高了其治療效果和精確度。靶向輸送機制和基於奈米粒子的配方等技術創新有望提高生物有效性並減少副作用。這些進步提高了藥物針對特定部位的能力，最佳化了血栓和心臟病等疾病的治療。此外，控制釋放技術和個人化藥物傳遞系統有助於改善患者的治療效果，進而推動尿激酶市場的需求和成長。

出血併發症的風險

出血併發症的風險將嚴重阻礙尿激酶市場的成長。尿激酶是一種溶栓劑，極有可能引起內出血，尤其是對於有潛在疾病或服用抗凝血劑的患者。這些安全問題限制了醫療保健提供者對尿激酶的採用，並促使謹慎開藥。此外，監管限制和更安全替代藥物的可用性進一步限制了市場擴張，對需求和整體市場表現產生負面影響。

COVID-19的影響

COVID-19 疫情嚴重擾亂了尿激酶市場，導致擇期手術延遲、住院人數減少以及供應鏈中斷。在疫情高峰期，對非新冠相關治療（包括尿激酶等溶栓藥物）的需求下降。然而，隨著醫療保健系統的穩定和外科手術的恢復，市場開始復甦。此外，人們對 COVID-19 患者血栓併發症的認知提高間接支持了對抗凝血和溶栓療法的需求。

預計尿激酶溶液細分市場在預測期內將佔據最大佔有率

預計在預測期內，尿激酶溶液部分將佔據最大的市場佔有率。尿激酶溶液，尤其是靜脈注射和局部形式，因其能夠快速溶解血栓，改善肺動脈栓塞和深層靜脈栓塞症等患者的預後而受到青睞。醫院和醫療機構擴大採用尿激酶製劑以及正在進行的研究也對該領域的市場擴張產生了積極影響。

預計深層靜脈栓塞症領域在預測期內將以最高複合年成長率成長

由於血栓性疾病盛行率的上升以及對早期診斷和治療的認知的提高，預計深層靜脈栓塞症部分將在預測期內出現最高成長率。尿激酶是一種溶栓劑，廣泛用於深部靜脈栓塞（DVT）患者的溶栓治療，其需求日益成長。醫療基礎設施的進步和人口老化也促進了市場擴張。這一趨勢使 DVT 成為尿激酶市場持續成長和創新的關鍵驅動力。

比最大的地區

預計亞太地區將在預測期內佔據最大的市場佔有率。這是由於心血管疾病的增加、認知的提高以及獲得先進治療的機會的改善推動了需求。這種成長正在刺激創新、鼓勵投資並改善開發中國家患者的治療效果。此外，政府支持和不斷擴大的醫療保健基礎設施正在加速市場滲透，使挽救生命的溶栓療法更容易獲得，最終有助於改善公共衛生並增強當地製藥業的前景。

複合年成長率最高的地區：

在預測期內，由於人們對溶栓療法的認知不斷提高，預計北美將呈現最高的複合年成長率。醫療保健基礎設施的進步、大型製藥公司的存在以及支持性法律規範進一步推動了市場擴張。老年人口的成長和對微創治療的需求將推動基於尿激酶的療法的採用。這些因素的結合顯著改善了患者的治療效果，刺激了區域市場的成長和創新。

免費客製化服務

訂閱此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球尿激酶市場類型

  • 尿激酶粉
  • 尿激酶溶液

6. 全球尿激酶市場（依來源）

  • 人類尿激酶
  • 重組尿激酶

7. 全球尿激酶市場（依給藥途徑）

  • 靜脈
  • 導管內部

8. 全球尿激酶市場（依應用）

  • 肺動脈栓塞
  • 深層靜脈栓塞症
  • 導管阻塞
  • 心肌梗塞
  • 其他用途

9. 全球尿激酶市場（依最終用戶）

  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他最終用戶

第10章全球尿激酶市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Syner-Med Ltd.
  • Microbix Biosystems Inc.
  • Wuxi Green Pharmaceutical Co., Ltd.
  • Jiangxi Haoran Bio-Pharma Co., Ltd.
  • Medicure Inc.
  • Lee's Pharmaceutical Holdings Ltd.
  • Taj Pharmaceuticals Limited
  • Jiangsu Techpool Bio-Pharma Co., Ltd.
  • Guangzhou Recomgen Biotech Co., Ltd.
  • LGM Pharma
  • ScienCell Research Laboratories, Inc.
  • BioVision, Inc.
  • Abbott Laboratories
  • Enzo Life Sciences, Inc.
  • Molecular Innovations, Inc.
  • Prospec-Tany Technogene Ltd.
  • Wuhan YZY Biopharma Co., Ltd.
  • GenScript Biotech Corporation
  • Chymotech AS
Product Code: SMRC29294

According to Stratistics MRC, the Global Urokinase Market is accounted for $2.08 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Urokinase is a thrombolytic enzyme used medically to dissolve blood clots in the body. It is a serine protease originally derived from human urine, but now commonly produced using recombinant DNA technology. Urokinase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the primary protein component of blood clots. It is primarily used to treat conditions such as pulmonary embolism, deep vein thrombosis, and catheter blockages. As a fibrinolytic agent, urokinase plays a vital role in restoring blood flow in occluded vessels, making it a critical therapeutic option in emergency and interventional medicine.

According to 2024 article by British Heart Foundation, 7.6 million people are living in with heart and circulatory disease in UK.

Market Dynamics:

Driver:

Rising Prevalence of Thrombotic Disorders

The growing incidence of thrombotic disorders is propelling the urokinase market due to the heightened need for thrombolytic treatments. The enzyme urokinase, which is employed to break down blood clots, plays a vital role in the treatment of conditions like pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. As the global prevalence of these disorders rises, particularly among aging populations, the demand for effective clot-dissolving treatments is increasing. This trend is benefiting the urokinase market and spurring further developments in its production and application.

Restraint:

High Treatment Costs

High treatment costs significantly hinder the growth of the urokinase market by limiting accessibility for patients and healthcare providers, particularly in low- and middle-income regions. These elevated expenses reduce the adoption of urokinase-based therapies, as more affordable alternatives are sought. Additionally, high costs strain healthcare budgets, discourage insurance coverage, and restrict widespread clinical use, ultimately slowing market expansion and impeding innovation in thrombolytic treatments.

Opportunity:

Technological Advancements in Drug Delivery

Technological advancements in drug delivery systems have significantly impacted the Urokinase market by enhancing its therapeutic efficacy and precision. Innovations such as targeted delivery mechanisms and nanoparticle-based formulations ensure better bioavailability and reduced side effects. These advancements improve the drug's ability to target specific sites, optimizing the treatment of conditions like blood clots and heart attacks. Additionally, controlled release technologies and personalized drug delivery systems contribute to improved patient outcomes, driving demand and growth within the Urokinase market.

Threat:

Risk of Bleeding Complications

The risk of bleeding complications significantly hinders the growth of the urokinase market. Urokinase, a thrombolytic agent, carries a high potential for causing internal bleeding, particularly in patients with underlying conditions or on anticoagulants. This safety concern limits its widespread adoption among healthcare providers, prompting cautious prescription practices. Additionally, regulatory restrictions and the availability of safer alternatives further restrain market expansion, negatively impacting demand and overall market performance.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the urokinase market due to delays in elective surgeries, reduced hospital admissions, and supply chain interruptions. Demand for non-COVID-related therapies, including thrombolytic agents like urokinase, declined during the peak of the pandemic. However, as healthcare systems stabilized and surgical procedures resumed, the market began recovering. Additionally, increased awareness of thrombotic complications in COVID-19 patients indirectly supported demand for anticoagulant and thrombolytic therapies.

The urokinase solution segment is expected to be the largest during the forecast period

The urokinase solution segment is expected to account for the largest market share during the forecast period because Urokinase solutions, particularly in intravenous and local delivery forms, are gaining preference due to their ability to rapidly dissolve blood clots, improving patient outcomes in conditions like pulmonary embolism and deep vein thrombosis. The growing adoption of urokinase solutions in hospitals and healthcare facilities, combined with ongoing research, is further fueling the segment's positive impact on market expansion.

The deep vein thrombosis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep vein thrombosis segment is predicted to witness the highest growth rate, due to the rising incidence of thrombotic disorders and increased awareness of early diagnosis and treatment. Urokinase, a thrombolytic agent, is widely used to dissolve blood clots in DVT patients, leading to its growing demand. Advancements in healthcare infrastructure and an aging population further contribute to market expansion. This trend positions DVT as a key driver fueling sustained growth and innovation in the urokinase market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cardiovascular cases, increased awareness, and improved access to advanced therapies are driving demand. This growth is fostering innovation, encouraging investments, and improving patient outcomes across developing nations. Additionally, government support and expanding healthcare infrastructure are accelerating market penetration, making life-saving thrombolytic therapies more accessible, ultimately contributing to better public health and a stronger regional pharmaceutical landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing awareness of thrombolytic therapies. Advancements in healthcare infrastructure, strong presence of key pharmaceutical players, and supportive regulatory frameworks further fuel market expansion. The growing geriatric population and demand for minimally invasive procedures enhance the uptake of urokinase-based treatments. Collectively, these factors are significantly improving patient outcomes and driving the regional market's growth and innovation.

Key players in the market

Some of the key players profiled in the Urokinase Market include Syner-Med Ltd., Microbix Biosystems Inc., Wuxi Green Pharmaceutical Co., Ltd., Jiangxi Haoran Bio-Pharma Co., Ltd., Medicure Inc., Lee's Pharmaceutical Holdings Ltd., Taj Pharmaceuticals Limited, Jiangsu Techpool Bio-Pharma Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., LGM Pharma, ScienCell Research Laboratories, Inc., BioVision, Inc., Abbott Laboratories, Enzo Life Sciences, Inc., Molecular Innovations, Inc., Prospec-Tany Technogene Ltd., Wuhan YZY Biopharma Co., Ltd., GenScript Biotech Corporation and Chymotech AS.

Key Developments:

In August 2024, Abbott and Medtronic announced a significant global partnership, to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aims to enhance diabetes management by enabling automatic insulin adjustments based on real-time glucose data.

In June 2024, Abbott has partnered with the National Association of Community Health Centers (NACHC) to improve access to nutritious food and health services. The collaboration aims to enhance healthcare delivery and address the growing health challenges related to nutrition in underserved communities.

Types Covered:

  • Urokinase Powder
  • Urokinase Solution

Sources Covered:

  • Human-derived Urokinase
  • Recombinant Urokinase

Routes of Administration Covered:

  • Intravenous
  • Intracatheter

Applications Covered:

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Catheter Occlusion
  • Myocardial Infarction
  • Other Application

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Urokinase Market, By Type

  • 5.1 Introduction
  • 5.2 Urokinase Powder
  • 5.3 Urokinase Solution

6 Global Urokinase Market, By Source

  • 6.1 Introduction
  • 6.2 Human-derived Urokinase
  • 6.3 Recombinant Urokinase

7 Global Urokinase Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous
  • 7.3 Intracatheter

8 Global Urokinase Market, By Application

  • 8.1 Introduction
  • 8.2 Pulmonary Embolism
  • 8.3 Deep Vein Thrombosis
  • 8.4 Catheter Occlusion
  • 8.5 Myocardial Infarction
  • 8.6 Other Application

9 Global Urokinase Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Other End Users

10 Global Urokinase Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Syner-Med Ltd.
  • 12.2 Microbix Biosystems Inc.
  • 12.3 Wuxi Green Pharmaceutical Co., Ltd.
  • 12.4 Jiangxi Haoran Bio-Pharma Co., Ltd.
  • 12.5 Medicure Inc.
  • 12.6 Lee's Pharmaceutical Holdings Ltd.
  • 12.7 Taj Pharmaceuticals Limited
  • 12.8 Jiangsu Techpool Bio-Pharma Co., Ltd.
  • 12.9 Guangzhou Recomgen Biotech Co., Ltd.
  • 12.10 LGM Pharma
  • 12.11 ScienCell Research Laboratories, Inc.
  • 12.12 BioVision, Inc.
  • 12.13 Abbott Laboratories
  • 12.14 Enzo Life Sciences, Inc.
  • 12.15 Molecular Innovations, Inc.
  • 12.16 Prospec-Tany Technogene Ltd.
  • 12.17 Wuhan YZY Biopharma Co., Ltd.
  • 12.18 GenScript Biotech Corporation
  • 12.19 Chymotech AS

List of Tables

  • Table 1 Global Urokinase Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 4 Global Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 5 Global Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 6 Global Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 7 Global Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 8 Global Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 9 Global Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 10 Global Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 11 Global Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 12 Global Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 13 Global Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 14 Global Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 15 Global Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 16 Global Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 17 Global Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 18 Global Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 19 Global Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 20 Global Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 21 Global Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 22 North America Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 23 North America Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 24 North America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 25 North America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 26 North America Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 27 North America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 28 North America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 29 North America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 30 North America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 31 North America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 32 North America Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 33 North America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 34 North America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 35 North America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 36 North America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 37 North America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 38 North America Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 39 North America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 40 North America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 41 North America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 42 North America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 43 Europe Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 44 Europe Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 45 Europe Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 46 Europe Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 47 Europe Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 48 Europe Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 49 Europe Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 50 Europe Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 51 Europe Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 52 Europe Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 53 Europe Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 54 Europe Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 55 Europe Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 56 Europe Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 57 Europe Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 58 Europe Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 59 Europe Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 60 Europe Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 61 Europe Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 62 Europe Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 63 Europe Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 64 Asia Pacific Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 65 Asia Pacific Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 66 Asia Pacific Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 67 Asia Pacific Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 68 Asia Pacific Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 69 Asia Pacific Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 70 Asia Pacific Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 71 Asia Pacific Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 72 Asia Pacific Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 73 Asia Pacific Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 74 Asia Pacific Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 75 Asia Pacific Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 76 Asia Pacific Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 77 Asia Pacific Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 78 Asia Pacific Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 79 Asia Pacific Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 80 Asia Pacific Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 81 Asia Pacific Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 82 Asia Pacific Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 83 Asia Pacific Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 84 Asia Pacific Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 85 South America Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 86 South America Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 87 South America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 88 South America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 89 South America Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 90 South America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 91 South America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 92 South America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 93 South America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 94 South America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 95 South America Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 96 South America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 97 South America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 98 South America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 99 South America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 100 South America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 101 South America Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 102 South America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 103 South America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 104 South America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 105 South America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 106 Middle East & Africa Urokinase Market Outlook, By Country (2024-2032) ($MN)
  • Table 107 Middle East & Africa Urokinase Market Outlook, By Type (2024-2032) ($MN)
  • Table 108 Middle East & Africa Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
  • Table 109 Middle East & Africa Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
  • Table 110 Middle East & Africa Urokinase Market Outlook, By Source (2024-2032) ($MN)
  • Table 111 Middle East & Africa Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
  • Table 112 Middle East & Africa Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
  • Table 113 Middle East & Africa Urokinase Market Outlook, By Administration (2024-2032) ($MN)
  • Table 114 Middle East & Africa Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 115 Middle East & Africa Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
  • Table 116 Middle East & Africa Urokinase Market Outlook, By Application (2024-2032) ($MN)
  • Table 117 Middle East & Africa Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
  • Table 118 Middle East & Africa Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
  • Table 119 Middle East & Africa Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
  • Table 120 Middle East & Africa Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
  • Table 121 Middle East & Africa Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
  • Table 122 Middle East & Africa Urokinase Market Outlook, By End User (2024-2032) ($MN)
  • Table 123 Middle East & Africa Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 124 Middle East & Africa Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 125 Middle East & Africa Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 126 Middle East & Africa Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)